Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030

CONCLUSION: NAT for TNBC reduced ctDNA TFx by 285-fold in responders and 24-fold in non-responders. In 58% (22/38) of patients, ctDNA TFx dropped below the detection level of a commercially available test, emphasizing the need for sensitive tests. Additional studies will determine if ctDNA-guided approaches can improve outcomes.PMID:37597579 | DOI:10.1016/j.annonc.2023.08.004

Source: Ann Oncol - August 19, 2023 Category: Cancer & Oncology Authors: H A Parsons T Blewett X Chu S Sridhar K Santos K Xiong V G Abramson A Patel J Cheng A Brufsky J Rhoades J Force R Liu T A Traina L A Carey M F Rimawi K D Miller V Stearns J Specht C Falkson H J Burstein A C Wolff E P Winer N Tayob I E Krop G M Makrigiorgo Source Type: research